TNF transactivation of EGFR stimulates cytoprotective COX-2 expression in gastrointestinal epithelial cells

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 301, Issue 2, 2011, Pages

  Hobbs, Stuart S ^a   Goettel, Jeremy A ^b   Liang, Dongchun ^a   Yan, Fang ^a   Edelblum, Karen L ^b   Frey, Mark R ^c   Mullane, Matthew T ^a   Polk, D Brent ^c  

^a Hepatology and Nutrition   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cyclooxygenase 2; Epidermal growth factor receptor; Tumor necrosis factor

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN TYROSINE KINASE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CELL TYPE; CELL VIABILITY; COLON EPITHELIAL CELL; COLON MUCOSA; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; INJECTION; INTESTINE EPITHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STOMACH EPITHELIUM; TRANSACTIVATION; WILD TYPE;

ANIMALS; CELL LINE; CELL SURVIVAL; COLON; CYCLOOXYGENASE 2; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STOMACH; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79961004564     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00383.2010     Document Type: Article

References (78)

1. Agoff SN, Brentnall TA, Crispin DA, Taylor SL, Raaka S, Haggitt RC, Reed MW, Afonina IA, Rabinovitch PS, Stevens AC, Feng Z, Bronner MP. The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am J Pathol 157: 737-745, 2000.
2. Andreev J, Galisteo ML, Kranenburg O, Logan SK, Chiu ES, Okigaki M, Cary LA, Moolenaar WH, Schlessinger J. Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signaling cascade. J Biol Chem 276: 20130-20135, 2001.
3. Argast GM, Campbell JS, Brooling JT, Fausto N. Epidermal growth factor receptor transactivation mediates tumor necrosis factor-induced hepatocyte replication. J Biol Chem 279: 34530-34536, 2004.
4. 2-dependent, relaxation of the cultured mouse trachea by increasing the activity of COX-2. Br J Pharmacol 144: 220-230, 2005.
5. Balkwill F. TNF-α in promotion and progression of cancer. Cancer Metastasis Rev 25: 409-416, 2006.
6. Berg DJ, Davidson N, Kudie;hn R, Muller W, Menon S, Holland G, Thompson-Snipes L, Leach MW, Rennick D. Enterocolitis and colon cancer in interleukin- 10-deficient mice are associated with aberrant cytokine production and CD4 TH1-like responses. J Clin Invest 98: 1010-1020, 1996.
7. Berg DJ, Zhang J, Weinstock JV, Ismail HF, Earle KA, Alila H, Pamukcu R, Moore S, Lynch RG. Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology 123: 1527-1542, 2002.
8. Blay J, Brown KD. Epidermal growth factor promotes the chemotactic migration of cultured rat intestinal epithelial cells. J Cell Physiol 124: 107-112, 1985.
9. Blobel C. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 6: 32-43, 2005.
10. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278: 35451-35457, 2003.
11. 125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts. J Cell Biol 71: 159-171, 1976.
12. Chun KS, Surh YJ. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 68: 1089-1100, 2004.
13. Daub H, Wallasch C, Lankenau A, Herrlich A, Ullrich A. Signal characteristics of G protein-transactivated EGF receptor. EMBO J 16: 7032-7044, 1997.
14. Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 14: 193-209, 2003.
15. Denkert C, Koch I, von Keyserlingk N, Noske A, Niesporek S, Dietel M, Weichert W. Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod Pathol 19: 1261-1269, 2006.
16. Edelblum KL, Goettel JA, Koyama T, McElroy SJ, Yan F, Polk DB. TNFR1 promotes TNF-mediated mouse colon epithelial cell survival through Raf activation of NF-κB. J Biol Chem 483: 29485-29494, 2008.
17. Edelblum KL, Yan F, Yamaoka T, Polk DB. Regulation of apoptosis during homeostasis and disease in the intestinal epithelium. Inflamm Bowel Dis 12: 413-424, 2006.
18. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G. Effects of nonsteroidal anti-inflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 95: 1949-1954, 2000.
19. Frey MR, Dise RS, Edelblum KL, Polk DB. p38 kinase regulates epidermal growth factor receptor downregulation and cellular migration. EMBO J 25: 5683-5692, 2006.
20. Frey MR, Hilliard VC, Mullane MT, Polk DB. ErbB4 promotes cyclooxygenase- 2 expression and cell survival in colon epithelial cells. Lab Invest 90: 1415-1424, 2010.
21. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, Subbaramaiah K, Cooper HS, Itzkowitz SH, Abreu MT. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133: 1869-1881, 2007.
22. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121: 241-246, 1994.
23. Greenberg ER, Baron JA, Freeman DH, Mandel JS, Haile R. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst 85: 912-916, 1993.
24. Groslash;vdal LM, Stang E, Sorkin A, Madshus IH. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res 300: 388-395, 2004.
25. Hegazi RA, Mady HH, Melhem MF, Sepulveda AR, Mohi M, Kandil HM. Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice. Inflamm Bowel Dis 9: 230-236, 2003.
26. Hehlgans T, Madie;nnel DN. The TNF-TNF receptor system. Biol Chem 383: 1581-1585, 2002.
27. Hobbs SS, Cameron EM, Hammer RP, Le AT, Gallo RM, Blommel EN, Coffing SL, Chang H, Riese DJ. Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase. Oncogene 23: 883-893, 2004.
28. Joseph RR, Yazer E, Hanakawa Y, Stadnyk AW. Prostaglandins and activation of AC/cAMP prevents anoikis in IEC-18. Apoptosis 10: 1221-1233, 2005.
29. Kaiser GC, Polk DB. Tumor necrosis factor- regulates proliferation in a mouse intestinal cell line. Gastroenterology 112: 1231-1240, 1997.
30. Karnes WE, Weller SG, Adjei PN, Kottke TJ, Glenn KS, Gores GJ, Kaufmann SH. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. Gastroenterology 114: 930-939, 1998.
31. Laudanno OM, Cesolari JA, Esnarriaga J, Rista L, Piombo G, Maglione C, Aramberry L, Sambrano J, Godoy A, Rocaspana A. Gastrointestinal damage induced by celecoxib and rofecoxib in rats. Dig Dis Sci 46: 779-784, 2001.
32. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 91: 837-844, 1986.
33. Lee CW, Lin CC, Lin WN, Liang KC, Luo SF, Wu CB, Wang SW, Yang CM. TNF-α induces MMP-9 expression via activation of Src/ EGFR, PDGFR/PI3K/Akt cascade and promotion of NF-κB/p300 binding in human tracheal smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 292: L799-L812, 2007.
34. Lee D, Cross SH, Strunk KE, Morgan JE, Bailey CL, Jackson IJ, Threadgill DW. Wa5 is a novel ENU-induced antimorphic allele of the epidermal growth factor receptor. Mamm Genome 15: 525-536, 2004.
35. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Beguinot L, Geiger B, Yarden Y. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 12: 3663-3674, 1998.
36. Lin WN, Luo SF, Wu CB, Lin CC, Yang CM. Lipopolysaccharide induces VCAM-1 expression and neutrophil adhesion to human tracheal smooth muscle cells: involvement of Src/EGFR/PI3-K/Akt pathway. Toxicol Appl Pharmacol 228: 256-268, 2008.
37. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276: 18563-18569, 2001.
38. Luetteke N, Phillips H, Qiu T, Copeland N, Earp H, Jenkins N, Lee D. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev 8: 399-413, 1994.
39. Luo JC, Shin VY, Yang YH, Wu WK, Ye YN, So WH, Chang FY, Cho CH. Tumor necrosis factor- stimulates gastric epithelial cell proliferation. Am J Physiol Gastrointest Liver Physiol 288: G32-G38, 2005.
40. MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A. Tumour necrosis factorα and interferon-γ production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 81: 301-305, 1990.
41. MacEwan DJ. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 14: 477-492, 2002.
42. Matuk R, Crawford J, Abreu MT, Targan SR, Vasiliauskas EA, Papadakis KA. The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis 10: 352-356, 2004.
43. 2-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J Biol Chem 275: 9572-9580, 2000.
44. Morson BC. Precancer and cancer in inflammatory bowel disease. Pathology 17: 173-180, 1985.
45. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, ReynoldsMM,Sloan D, Theleman A, Miller P. Induction of apoptosis and cell cycle arrest by CP-358774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57: 4838-4848, 1997.
46. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor- by immunohistochemistry in chronic inflammatory bowel disease. Gut 34: 1705-1709, 1993.
47. Oguma K, Oshima H, Aoki M, Uchio R, Naka K, Nakamura S, Hirao A, Saya H, Taketo M, Oshima M. Activated macrophages promote Wnt signalling through tumour necrosis factor- in gastric tumour cells. EMBO J 27: 1671-1681, 2008.
48. Polk DB. Ontogenic regulation of phospholipase C-γ1 activity and expression in the rat small intestine. Gastroenterology 107: 109-116, 1994.
49. Polk DB, Tong W. Epidermal and hepatocyte growth factors stimulate chemotaxis in an intestinal epithelial cell line. Am J Physiol Cell Physiol 277: C1149-C1159, 1999.
50. Popivanova B, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, Oshima M, Fujii C, Mukaida N. Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118: 560-570, 2008.
51. Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 98: 2076-2085, 1996.
52. Riehl T, Newberry RD, Lorenz RG, Stenson W. TNFR1 mediates the radioprotective effects of lipopolysaccharide in the mouse intestine. Am J Physiol Gastrointest Liver Physiol 286: G166-G173, 2004.
53. Roessner A, Kuester D, Malfertheiner P, Schneider-Stock R. Oxidative stress in ulcerative colitis-associated carcinogenesis. Pathol Res Pract 204: 511-524, 2008.
54. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462-2476, 2005.
55. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126: 451-459, 2004.
56. Scheinin T, Butler DM, Salway F, Scallon B, Feldmann M. Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis. Clin Exp Immunol 133: 38-43, 2003.
57. Sethi G, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer. Front Biosci 13: 5094-5107, 2008.
58. 2-stimulated intestinal epithelial proliferation and angiogenesis. Cancer Res 66: 846-855, 2006.
59. 4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 86: 453-460, 1984.
60. Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz- Behoftsitz C, Palizban A, Pombo J, Watts J, Morham SG, Bjarnason I. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 122: 1913-1923, 2002.
61. Singer CA, Baker KJ, McCaffrey A, AuCoin DP, Dechert MA, Gerthoffer WT. p38 MAPK and NF-κB mediate COX-2 expression in human airway myocytes. Am J Physiol Lung Cell Mol Physiol 285: L1087-L1098, 2003.
62. Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115: 297-306, 1998.
63. Singhirunnusorn P, Ueno Y, Matsuo M, Suzuki S, Saiki I, Sakurai H. Transient suppression of ligand-mediated activation of epidermal growth factor receptor by tumor necrosis factor-α through the TAK1-p38 signaling pathway. J Biol Chem 282: 12698-12706, 2007.
64. Sizemore N, Cox AD, Barnard JA, Oldham SM, Reynolds ER, Coffey RJ. Pharmacological inhibition of Ras-transformed epithelial cell growth is linked to down-regulation of epidermal growth factorrelated peptides. Gastroenterology 117: 567-576, 1999.
65. Subbaramaiah K, Marmo TP, Dixon DA, Dannenberg AJ. Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem 278: 37637-37647, 2003.
66. Sureban SM, Ramalingam S, Natarajan G, May R, Subramaniam D, Bishnupuri KS, Morrison AR, Dieckgraefe BK, Brackett DJ, Postier RG, Houchen CW, Anant S. Translation regulatory factor RBM3 is a protooncogene that prevents mitotic catastrophe. Oncogene 27: 4544-4556, 2008.
67. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor for Crohns disease. Crohns Disease cA2 Study Group. N Engl J Med 337: 1029-1035, 1997.
68. Tessner TG, Muhale F, Riehl T, Anant S, Stenson W. Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving Akt activation and bax translocation. J Clin Invest 114: 1676-1685, 2004.
69. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW. Aspirin use and risk of fatal cancer. Cancer Res 53: 1322-1327, 1993.
70. Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 38: 1654-1661, 2006.
71. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501, 1995.
72. Ueno Y, Sakurai H, Matsuo M, Choo M, Koizumi K, Saiki I. Selective inhibition of TNF-α -induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib. Br J Cancer 92: 1690-1695, 2005.
73. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 10: 45-65, 2003.
74. Whitehead RH, Robinson PS. Establishment of conditionally immortalized epithelial cell lines from the intestinal tissue of adult normal and transgenic mice. Am J Physiol Gastrointest Liver Physiol 296: G455-G460, 2009.
75. Wilson AJ, Gibson PR. Role of epidermal growth factor receptor in basal and stimulated colonic epithelial cell migration in vitro. Exp Cell Res 250: 187-196, 1999.
76. Yamaoka T, Yan F, Cao H, Hobbs SS, Dise RS, Tong W, Polk DB. Transactivation of EGF receptor and ErbB2 protects intestinal epithelial cells from TNF-induced apoptosis. Proc Natl Acad Sci USA 105: 11772-11777, 2008.
77. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
78. Zins K, Abraham D, Sioud M, Aharinejad S. Colon cancer cell-derived tumor necrosis factor-α mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway. Cancer Res 67: 1038-1045, 2007.